AI Article Synopsis
Article Abstract
Importance: Overactive bladder (OAB) is prevalent in older adults in whom management is complicated by comorbidities and greater vulnerability to the cognitive effects of antimuscarinic medications.
Objectives: The aim of this study is to provide a comprehensive evidence-based summary of the 2021 State-of-the-Science (SOS) conference and a multidisciplinary expert literature review on OAB and cognitive impairment.
Study Design: The American Urogynecologic Society and the Pelvic Floor Disorders Research Foundation convened a 3-day collaborative conference. Experts from multidisciplinary fields examined cognitive function, higher neural control of the OAB patient, risk factors for cognitive impairment in older patients, cognitive effects of antimuscarinic medications for OAB treatment, OAB phenotyping, conservative and advanced OAB therapies, and the need for a multidisciplinary approach to person-centered treatment. Translational topics included the blood-brain barrier, purine metabolome, mechanotransduction, and gene therapy for OAB targets.
Results: Research surrounding OAB treatment efficacy in cognitively impaired individuals is limited. Short- and long-term outcomes regarding antimuscarinic effects on cognition are mixed; however, greater anticholinergic burden and duration of use influence risk. Oxybutynin is most consistently associated with negative cognitive effects in short-term, prospective studies. Although data are limited, beta-adrenergic agonists do not appear to confer the same cognitive risk.
Conclusions: The 2021 SOS summary report provides a comprehensive review of the fundamental, translational, and clinical research on OAB with emphasis on cognitive impairment risks to antimuscarinic medications. Duration of use and antimuscarinic type, specifically oxybutynin when examining OAB treatments, appears to have the most cognitive impact; however, conclusions are limited by the primarily cognitively intact population studied. Given current evidence, it appears prudent to minimize anticholinergic burden by emphasizing nonantimuscarinic therapeutic regimens in the older population and/or those with cognitive impairment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/SPV.0000000000001272 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Cognitive impairment in young adults after cancer treatment: A descriptive correlational study on levels and associations with disease-related, psychological, and lifestyle factors.
J Psychosoc Oncol
December 2024
School of Human Kinetics, University of Ottawa, Ottawa, Ontario, Canada.
Purpose: Young adults report challenges concerning cancer--related cognitive impairment (CRCI). This study aimed to: (1) describe cognition in young adults post-cancer treatment using self-report and performance-based measures, and (2) examine associations between cognition and relevant disease-related, psychological, and lifestyle (physical activity; PA) factors.
Methods: Forty-six young adults (M = 31.
Exploring the effect and mechanism of action of Jinlida granules (JLD) in the treatment of diabetes-associated cognitive impairment based on network pharmacology with experimental validation.
Ann Med
December 2025
Department of Hebei Provincial Key Laboratory of Basic Medicine for Diabetes, The Shijiazhuang Second Hospital, Shijiazhuang, China.
Objectives: To explore the effect and the probable mechanisms of JLD in the treatment of type 2 diabetes mellitus (T2DM) - associated cognitive impairment (TDACI).
Methods: The effect of JLD in combating TDACI was assessed in T2DM model mice by conducting Morris water maze (MWM) behaviour testing. Active components and their putative targets, as well as TDACI-related targets, were collected from public databases.
Clinical validity and reproducibility of a visual rating scale for cingulate island sign in a real-world memory clinic: An FDG-PET/MRI study.
Eur J Neurol
January 2025
Padova Neuroscience Center (PNC), University of Padova, Padova, Italy.
Purpose: Brain [18F]FDG-PET is a supportive biomarker for cognitive impairment in Lewy bodies disease (LBD) showing reduced occipital metabolism and presence of the cingulate island sign (CIS), a relative preservation of posterior cingulate cortex (PCC) metabolism compared with precuneus and cuneus. We assess validation, clinical utility, and reproducibility of a qualitative visual CIS scale in the differential diagnosis with Alzheimer's disease (AD) in a memory clinic setting.
Methods: Sixty-seven patients were studied: 36 LBD, of whom 30 with dementia (DLB) and 6 with mild cognitive impairment (MCI-LB), and 31 AD (20 typical and 11 atypical presentations).
segcsvd: A Convolutional Neural Network-Based Tool for Quantifying White Matter Hyperintensities in Heterogeneous Patient Cohorts.
Hum Brain Mapp
December 2024
SEB Centre for Brain Resilience & Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Canada.
White matter hyperintensities (WMH) of presumed vascular origin are a magnetic resonance imaging (MRI)-based biomarker of cerebral small vessel disease (CSVD). WMH are associated with cognitive decline and increased risk of stroke and dementia, and are commonly observed in aging, vascular cognitive impairment, and neurodegenerative diseases. The reliable and rapid measurement of WMH in large-scale multisite clinical studies with heterogeneous patient populations remains challenging, where the diversity of imaging characteristics across studies adds additional complexity to this task.
View Article and Find Full Text PDFGender Differences in Dendritic Damage, Gut Microbiota Dysbiosis, and Cognitive Impairment During Aging Processes.
CNS Neurosci Ther
December 2024
Department of Radiology, The Affiliated Panyu Central Hospital of Guangzhou Medical University, Guangzhou, China.
Background: Cognitive impairment is a common and feared characteristic of aging processes, and one key mechanism of cognition is hippocampal synaptic structure. Previous studies have reported that gut microbiota dysbiosis occurred in neurodegenerative diseases and other brain disorders with cognitive impairment. However, it is not clear how gender differences affect cognitive impairment in aging processes and whether they affect synaptic structure and gut microbiota.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!